ImmunoGen, Inc. (Nasdaq: IMGN), a
leader in the expanding field of antibody-drug conjugates (ADCs)
for the treatment of cancer, today announced that three abstracts
highlighting two of the Company’s experimental ADC therapies,
IMGN632 and IMGN779, have been accepted for presentations at the
upcoming American Society of Hematology (ASH) Annual Meeting to be
held December 9-12, 2017, in San Diego.
Both IMGN779 and IMGN632 use ImmunoGen's novel
indolino-benzodiazepine payloads called IGNs, which alkylate DNA
without crosslinking. IMGN779 is a CD33-targeted ADC for the
treatment of acute myeloid leukemia (AML) currently in Phase 1
testing. IMGN632 is a CD123-targeted ADC for hematological
malignancies, including AML and blastic plasmacytoid dendritic cell
neoplasm (BPDCN). Last month, the Company announced that the
Investigational New Drug application for IMGN632 is active and it
expects to open a Phase 1 trial later this year.
“The clinical and preclinical data being presented at ASH
demonstrate the early potential of our novel IGN portfolio,” said
Richard Gregory, Ph.D., executive vice president and chief
scientific officer of ImmunoGen. “One of our strategic priorities
is to accelerate the development of these unique and highly
differentiated assets. IMGN779 and IMGN632 use our IGN payloads,
which were designed to meet the dual challenges of achieving high
potency against target cells, while having a tolerability profile
that enables continued patient treatment.”
In a poster presentation, the Company will report updated data
evaluating the safety and anti-leukemia activity from the dose
escalation phase of the IMGN779 first-in-human trial. In a separate
presentation, preclinical data evaluating the mechanism,
anti-leukemia efficacy, and tolerability of repeated dosing of
IMGN779 and cytarabine in combination using in vitro and in vivo
human AML preclinical models will be reported. Lastly, preclinical
data reporting the prevalence of CD123 expression in acute
lymphoblastic leukemia (ALL), and assessing the anti-leukemia
activity of IMGN632 on ALL cells will be presented in a poster
presentation.
Poster Presentations
- Title (Abstract #1357): “IMGN779, a
Next Generation CD33-Targeting ADC, Combines Effectively With
Cytarabine in Acute Myeloid Leukemia (AML) Preclinical Models,
Resulting in Increased DNA Damage Response, Cell Cycle Arrest and
Apoptosis In Vitro, and Prolonged Survival In Vivo”
- Poster session #616: Saturday, December
9, 5:30 – 7:30 PM PST.
- Title (Abstract #1312): “IMGN779, a
Next-Generation CD33-Targeting Antibody-Drug Conjugate (ADC)
Demonstrates Initial Antileukemia Activity in Patients with
Relapsed or Refractory Acute Myeloid Leukemia”
- Poster session #613: Saturday, December
9, 5:30 – 7:30 PM PST.
- Title (Abstract #2718): “CD123
Expression Patterns and Potential of IMGN632, a CD123-Targeted
Antibody Drug Conjugate, in Acute Lymphoblastic Leukemia”
- Poster session #618: Sunday, December
10, 6:00 – 8:00 PM PST.
Additional information can be found at www.hematology.org,
including abstracts.
About IMGN779IMGN779 is a novel ADC that combines a
high-affinity, humanized anti-CD33 antibody, a cleavable disulfide
linker, and one of ImmunoGen’s novel indolino-benzodiazepine
payloads, called IGNs, which alkylate DNA without crosslinking,
resulting in potent preclinical anti-leukemia activity with
relative sparing of normal hematopoietic progenitor cells.1,2
IMGN779 is in Phase 1 clinical testing for the treatment of
AML.
About IMGN632IMGN632 is a humanized anti-CD123
antibody-drug conjugate that is a potential treatment for AML,
BPDCN, myelodysplastic syndrome, B-cell acute lymphocytic leukemia,
and other CD123-positive malignancies. IMGN632 uses a novel IGN
payload, linker and antibody technology and in AML xenograft models
has demonstrated a large therapeutic index.3
About IGNsIndolino-benzodiazepine cancer-killing agents,
or IGNs, are a new class of cancer-killing agent developed by
ImmunoGen for use in ADCs. These ultra-potent, DNA-acting IGNs
alkylate DNA without crosslinking, which preclinically has resulted
in potent anti-leukemia activity with relative sparing of normal
hematopoietic progenitor cells.4,5 IMGN779, a CD33-targeting ADC in
Phase 1 testing for AML, was the first IGN ADC to enter clinical
testing.
About Acute Myeloid Leukemia (AML)AML is a cancer of the
bone marrow cells that produce white blood cells. It causes the
marrow to increasingly generate abnormal, immature white blood
cells (blasts) that do not mature into effective infection-fighting
cells. The blasts quickly fill the bone marrow, impacting the
production of normal platelets and red blood cells. The resulting
deficiencies in normal blood cells leave the patient vulnerable to
infections, bleeding problems and anemia.
It is estimated that, in the U.S. alone, 21,380 patients will be
diagnosed with AML this year and 10,590 patients will die from the
disease.6
About ImmunoGen, Inc.ImmunoGen is a clinical-stage
biotechnology company that develops targeted cancer therapeutics
using its proprietary ADC technology. The Company’s lead product
candidate, mirvetuximab soravtansine, is in a Phase 3 trial for
FRα-positive platinum-resistant ovarian cancer, and is in a
Phase 1b/2 trial in combination regimens for earlier-stage
disease. ImmunoGen has three additional clinical-stage product
candidates, two of which are being developed in collaboration with
Jazz Pharmaceuticals. ImmunoGen's ADC technology is also used in
Roche's marketed product, Kadcyla®, and in programs in development
by Amgen, Bayer, Biotest, CytomX, Debiopharm, Lilly, Novartis,
Sanofi and Takeda. More information about the Company can be found
at www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member of the
Roche Group.
1 S. Adams et al, Abstract P526, Presented at the
22nd Congress of the European Hematology
Association, June 22-25, 2017.2 Y. Kotvun et al.
(2016) Blood 128:768.3 S. Adams et al, Abstract
2832, Presented at the American Society of
Hematology, December 3-6, 2016.4 S. Adams et al,
2017.5 Y. Kotvun, 2016.6American Cancer Society (2016), About
Acute Myeloid Leukemia.
This press release includes forward-looking statements. For
these statements, ImmunoGen claims the protection of the safe
harbor for forward-looking statements provided by the Private
Securities Litigation Reform Act of 1995. It should be noted that
there are risks and uncertainties related to the development of
novel anticancer products, including IMGN779 and IMGN632, including
risks related to preclinical and clinical studies, their timings
and results. A review of these risks can be found in ImmunoGen's
Transition Report on Form 10-KT for the six-month transition period
ended December 31, 2016 and other reports filed with the Securities
and Exchange Commission.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171101005211/en/
For InvestorsImmunoGen, Inc.Sarah Kiely,
781-895-0600sarah.kiely@immunogen.comorFor MediaImmunoGen,
Inc.Courtney O'Konek,
781-895-0600courtney.okonek@immunogen.comorRobert StanislaroFTI
Consulting, Inc.,
212-850-5657robert.stanislaro@fticonsulting.com
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Apr 2023 to Apr 2024